Introduction-Pyrazinamide (PZA) is essential in tuberculosis (TB) treatment. We describe the prevalence, trends and predictors of PZA resistance in Mycobacterium tuberculosis complex (MTBC) in the U.S.
Introduction
Pyrazinamide (PZA) is an important component of first-line and second-line regimens for treatment of drug-susceptible and multidrug-resistant (MDR) tuberculosis (TB) [1] [2] [3] . PZA has remarkable sterilizing effects, playing a unique role in killing semi-dormant TB bacilli not easily killed by other antibiotics [4, 5] . In drug-susceptible TB, adding PZA to rifampin and isoniazid allowed shortening the duration of treatment from 9 to 6 months in most patients [6, 7] . Recent murine and human early bactericidal activity studies of novel drug regimens, demonstrated PZA was essential to well-performing regimens [8] [9] [10] .
Growth-based testing for PZA resistance is difficult because the drug is active only in an acidic microenvironment (pH 5.5), but such low pH itself inhibits the growth of Mycobacterium tuberculosis complex (MTBC). Further, even modest variations in inoculum size can alter the pH and lead to differing results [11, 12] . For these technical reasons, most countries and some mycobacteriology laboratories in the U.S. do not test for PZA susceptibility, and the global extent of PZA resistance is largely unknown. The Clinical and Laboratory Standards Institute recommended the BACTEC 460TB (BD, Sparks, MD, USA) as a reference method for PZA susceptibility testing [13] . However, in 2011 BD stopped producing reagents for the BACTEC 460TB system, so BACTEC Mycobacteria Growth Indicator Tube ® (MGIT) 960 system (BD, Sparks, MD, USA) and VersaTREK ® (TREK Diagnostic Systems, Inc., Cleveland, OH, USA) are currently the only Food and Drug Administration (FDA) cleared systems for PZA drug susceptibility testing (DST) [14] . These systems, however, may have a higher potential for false-resistant test results for PZA resistance than the BACTEC 460TB [12, 15] .
Mycobacterium bovis, a member of MTBC, is intrinsically resistant to PZA, and PZAmonoresistance is characteristic of M. bovis [16, 17] . In the U.S., M. bovis is transmitted to humans primarily by ingestion of unpasteurized dairy products and more often involves extrapulmonary sites of disease [18, 19] .
Because PZA will likely remain a central component in the treatment of tuberculosis for the foreseeable future, it is critically important to understand the epidemiology of PZA resistance. We describe the prevalence, trends, and risk factors for initial resistance to PZA among MTBC cases in the U.S.
Methods

Case reporting
The U.S. National TB Surveillance System (NTSS) at the U.S. Centers for Disease Control and Prevention (CDC) has collected nationwide TB incidence data since 1953 [20] . We analyzed data on all verified, culture-positive tuberculosis cases reported by the 50 states and the District of Columbia through the Report of Verified Case of Tuberculosis (RVCT) form between 1 January 1999 and 31 December 2009. The RVCT form includes sociodemographic and clinical information as well as DST results based on the initial positive culture of sputum or other specimen [21] . We examined overall and annual proportions of culture-positive MTBC cases with reported initial DST results for PZA. For this analysis, we excluded TB cases without reported DST results for isoniazid (INH), rifampin (RMP), and ethambutol (EMB). We also excluded states where the overall proportion of culture-positive TB cases with reported initial DST results to PZA was <85% during the study period.
Since data about sub-species are not available to most clinicians who treat TB (as the majority of the US public health labs use Accuprobe™ tests for culture identification reported as MTBC, and the genotype data which identifies sub-species are not immediately available) [ 
Definitions
"Drug-susceptible" was defined as susceptibility to INH, RMP, EMB, and PZA. MDR was defined as resistance to at least INH and RMP. "PZA monoresistance" was defined as resistance to PZA, and susceptibility to INH, RMP and EMB. "PZA polyresistance" was defined as resistance to PZA with additional resistance to INH, RMP, or EMB, but not both INH and RMP.
"Acquired" resistance to an anti-TB drug was used to describe a case in which the DST of the initial isolate was recorded as "susceptible," and that of the final isolate was recorded as "resistant" to the same drug.
Statistical analyses
Statistical analyses were performed using SAS software, version 9.1 (SAS Institute Inc., Cary, NC). A P value of ≤0.05 was considered statistically significant. Risk factors associated with PZA resistance were determined among cases with MTBC, and among a subset of cases with infection with Mtb for 2004-2009 after matching with genotyping data. Prevalence ratios (PR) with 95% confidence intervals (CI) were calculated. Factors significant at a value of P≤0.05 and plausible epidemiological or biological associations with PZA resistance were included in a multivariable log-binomial regression model. We used backward selection starting with all candidate variables selected based on statistical criteria and plausible epidemiological or biological associations with PZA resistance and tested if the deletion of variables improved precision around point estimates in the model, repeating this process until no further improvement was possible.
For testing the significance of trends, we assessed the slope of the regression line using Poisson regression for event count data. Annual Percent Change (APC) in rates with confidence limits (CL) was calculated using Joinpoint Regression Program, Version 3.5. 
Results
PZA resistance proportions, trends, and predictors in MTBC cases
During the 11-year study period, 125,778 culture positive MTBC cases were reported by the 50 U.S. states and the District of Columbia (Figure 1) . In 36 states and 2 other public health jurisdictions, the proportion of culture-positive MTBC cases that had DST results reported to the NTSS for PZA was ≥85% (Figure 2A) , amounting to 82,672 TB cases. Of these, 79,321 (95.9%) had DST result for all 4 first-line drugs and were included in the analysis (Figure 1) . A total of 2,167 (2.7%) cases had initial PZA resistance: 1,441 (66.5%) were PZA-monoresistant, 312 (14.4%) were PZA-polyresistant and 414 (19.1%) were PZAresistant MDR cases. Resistance to PZA was reported in 2.2% of non-MDR cases, and 38.0% of MDR cases. In the 14 states excluded from analysis, <50% of cases per year had a DST result for PZA during the study period, with the exception of 2009 ( Figure 2B ). A total of 4,961 cases were alive at diagnosis, initially treated with PZA and had both initial and final DST result to PZA reported to the NTSS. Of 4,769 (96.1% of 4961) cases with an initial isolate reported as PZA-susceptible, 36 (0.8%) cases had a final DST reported as resistant (i.e., "acquired" resistance to PZA).
Results of descriptive analysis of predictors of monoresistance, polyresistance, and PZA resistance with MDR in MTBC cases are shown in Figure 1A ). Among 28,080 MTBC isolates, the proportions of PZAmonoresistance increased significantly (P=0.004) ( Figure 3B ). This trend remained significant when M. bovis was excluded (P=0.02), although proportions of monoresistance to PZA were approximately three times lower in the sub-set of Mtb cases compared to MTBC ( Figure 3C ). Figure 1A) . Similarly, the proportion of PZA-monoresistance significantly increased among Mtb cases infected with Indo-Oceanic (APC=14.2, CL: 7.0-21.8; P=0.005) and East African Indian (APC=38.6, CL: 1.0-90.3; P=0.05) isolates, but not among other lineages.
Predictors of PZA resistance in M. tuberculosis cases
The results of multivariable analysis examining the associations between clinical and demographic characteristics and PZA resistance in Mtb cases are presented in Table 3 . The patient characteristics associated with PZA resistance in the subset of cases with Mtb differed from those for all MTBC cases. Among cases with Mtb, PZA mono-resistance was associated with Asian race and extrapulmonary TB. When Mtb lineage was included in the multivariable model, PZA monoresistance was associated with Indo-Oceanic lineage and was no longer associated with race or site of disease ( [18] . Indeed, two thirds of all PZA-monoresistant cases were among cases with M. bovis. In contrast, among MDR TB cases, PZA resistance was higher in females, in cases with previous TB, and almost exclusively in MTB species. Interestingly, the adjusted prevalence of PZA polyresistance, compared to drug-susceptible TB, included a mix of risk factors found for PZA monoresistance and PZA resistance in MDR, likely reflecting the broader mix of M. bovis and MTB species. Clinicians should be aware that patients with certain characteristics are more likely to have PZA-resistant TB. However, our findings confirm previous reports that PZA monoresistance is not a reliable marker of M. bovis [18, 35, 36] . Although not typically available for initial case management, species identification is important to better understand these findings.
Factors associated with PZA resistance among cases of Mtb are less well understood. In the analysis of only cases with Mtb we found that PZA monoresistance was associated with Asian race rather than Hispanic ethnicity, and with exclusively extrapulmonary disease. Because site of disease has been shown to be associated with Mtb lineage [24, 37] , and these lineages are differentially associated with human populations globally[38], we sought to determine whether the patient characteristics associated with Mtb PZA monoresistance reflected differences in Mtb lineage. In multivariable analysis including Mtb lineage, only Indo-Oceanic lineage remained significantly associated with PZA monoresistance, suggesting that bacterial lineage, rather than host characteristic, was the primary association. Globally, Indo-Oceanic lineage is primarily localized to South and Southeast Asia[38]. Our findings suggest two possible hypotheses for the association between PZA monoresistance and Indo-Oceanic lineage. First, this may reflect a biological difference by lineage in the propensity towards development of resistance to this drug. Second, these results would also be consistent with international differences in rates of PZA resistance (e.g. due to regional or national programmatic differences in TB treatment). Over half of all TB cases in the US are foreign-born [20] .
In contrast to other first-line drugs (including any resistance and monoresistance to INH or rifampin as well as MDR) [20] , the proportion of cases with reported resistance to PZA increased in the U.S. from 2.0% to 3.3%, 65% relative increase, largely due to an increase in PZA-monoresistance. Since PZA-monoresistance is characteristic of M. bovis, we assessed proportions of M. bovis in a sub-set of MTBC cases with genotyping results available for 2004-2009. M. bovis did not significantly increase, and the proportion of PZAmonoresistance increased irrespective of M. bovis. The prevalence of PZA resistance differed among different lineages of Mtb and the relative prevalence of these lineages among TB isolates was changing over time in our study population. Among MDR TB cases, PZA resistance was significantly higher in the East Asian lineage, while in non-MDR cases PZA resistance was significantly higher in the Indo-Oceanic lineage. Even though the proportion of PZA resistance among isolates from MDR TB cases is much higher than those among non-MDR cases, there were only 1,090 MDR TB cases in this analysis compared with 78,231 non-MDR TB cases. Both the proportion of TB cases with Indo-Oceanic lineage and the proportion of Indo-Oceanic cases with PZA resistance increased over time. Therefore, given that increasing PZA monoresistance in the U.S. does not appear to be related to M. bovis, it may be related to increases in the proportion of Indo-Oceanic strains. An increase in the proportion of Indo-Oceanic strains could be related to an increase in the proportion of cases in the U.S. among foreign-born persons from regions in which the IndoOceanic lineage is common.
On the other hand, because MGIT 960 has been shown to have higher rates of false-resistant results compared to the BACTEC 460 system [15, 39] , we considered that increasing proportions of PZA monoresistance might reflect the progressive change from BACTEC 460TB to MGIT 960 after FDA clearance in 2002 [40] . However, PZA resistance began increasing 3 years earlier, in 1999, and did not accelerate after 2002, suggesting the change in technology may not be the main reason behind the trend in PZA DST results.
Our analysis was subject to several important limitations. The main limitation is restriction of the analysis to 38 public health jurisdictions that routinely test for susceptibility to PZA. For the other 14 states the prevalence and trends may have been due to selection bias. Thus, the study findings may not generalize to the whole country. However, the overall proportion of cases with reported PZA resistance during 1999-2009 was similar in the jurisdictions included in analysis (2.7%) and the 14 states excluded (2.9%); in both subsets, the proportions of resistance to PZA were significantly increasing. Second, the genotyping data was limited to [2004] [2005] [2006] [2007] [2008] [2009] PZA resistance in terms of absolute numbers represents a small fraction of U.S. TB cases, but the increasing trend in PZA resistance makes it an important public health problem because PZA is an essential part of treatment [1] [2] [3] [8] [9] [10] . Thus, DST for PZA is critical. The trend in PZA resistance calls attention to the limitations of growth-based DST for PZA, although meticulous attention to the size of the inoculum seems to improve its reproducibility [12] . Nonetheless, the development of faster, more reliable laboratory methods to detect PZA resistance is a priority [ 
